Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-19
DOI
10.1186/s13046-021-01865-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Acquisition of cabozantinib-sensitive MET D1228N mutation during progression on crizotinib in MET-amplified triple-negative breast cancer
- (2020) Benjamin M. Parsons et al. Clinical Breast Cancer
- MicroRNA‐based risk scoring system to identify early‐stage oral squamous cell carcinoma patients at high‐risk for cancer‐specific mortality
- (2020) Angela J. Yoon et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- CUL4B contributes to cancer stemness by repressing tumor suppressor miR34a in colorectal cancer
- (2020) Yanjun Li et al. Oncogenesis
- Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma
- (2020) Rushdi S. Fadhil et al. PLoS One
- Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
- (2020) Mototsugu Shimokawa et al. Trials
- Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
- (2020) M. Schuler et al. ANNALS OF ONCOLOGY
- The Role of a Proprotein Convertase Inhibitor in Reactivation of Tumor-Associated Macrophages and Inhibition of Glioma Growth
- (2020) Mélanie Rose et al. Molecular Therapy-Oncolytics
- Long Non-Coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) Promotes Proliferation and Metastasis of Osteosarcoma Cells by Targeting c-Met and SOX4 via miR-34a/c-5p and miR-449a/b
- (2019) Zhenyu Sun et al. MEDICAL SCIENCE MONITOR
- MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer
- (2019) Yueh-Shan Weng et al. Molecular Cancer
- MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
- (2019) Ofra Novoplansky et al. INTERNATIONAL JOURNAL OF CANCER
- ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer
- (2019) Xiaofei Xin et al. ACS Applied Materials & Interfaces
- LncRNA SNHG7 contributes to tumorigenesis and progression in breast cancer by interacting with miR-34a through EMT initiation and the Notch-1 pathway
- (2019) Xianfu Sun et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- microRNA‐34a aggravates coxsackievirus B3‐induced apoptosis of cardiomyocytes through the SIRT1‐p53 pathway
- (2019) Dehua Jiang et al. JOURNAL OF MEDICAL VIROLOGY
- MALAT1 regulates miR-34a expression in melanoma cells
- (2019) Fei Li et al. Cell Death & Disease
- MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells
- (2019) Shun-Zhen Zheng et al. WORLD JOURNAL OF GASTROENTEROLOGY
- miR-34a inhibits proliferation, migration and invasion of paediatric neuroblastoma cells via targeting HNF4α
- (2019) Zhiping Li et al. Artificial Cells Nanomedicine and Biotechnology
- miR-34a as hub of T cell regulation networks
- (2019) Martin Hart et al. Journal for ImmunoTherapy of Cancer
- C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway
- (2019) Mingyuan Zhao et al. CANCER BIOLOGY & THERAPY
- p53, miR-34a and EMP1—Newly Identified Targets of TFF3 Signaling in Y79 Retinoblastoma Cells
- (2019) Maike Busch et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
- (2019) Yuting Liu et al. CLINICAL CANCER RESEARCH
- Layer‐by‐layer assembled PLGA nanoparticles carrying miR‐34a cargo inhibit the proliferation and cell cycle progression of triple‐negative breast cancer cells
- (2019) Chintan H. Kapadia et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
- Expression of miR-34a-5p is up-regulated in human colorectal cancer and correlates with survival and clock gene PER2 expression
- (2019) Kristina Hasakova et al. PLoS One
- Expanding the Transcriptome of Head and Neck Squamous Cell Carcinoma Through Novel MicroRNA Discovery
- (2019) Leigha D. Rock et al. Frontiers in Oncology
- Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives
- (2019) Marta Cristaldi et al. Frontiers in Physiology
- Emerging role of non-coding RNA in oral cancer
- (2018) Fatemeh Momen-Heravi et al. CELLULAR SIGNALLING
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion
- (2018) Yen-Han Tseng et al. Journal of Thoracic Oncology
- MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines
- (2018) Cecilia M. Lopez et al. PLoS One
- miR-34a directly targets tRNAiMetprecursors and affects cellular proliferation, cell cycle, and apoptosis
- (2018) Bo Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Correction Alternative mechanisms of miR-34a regulation in cancer
- (2018) Eva Slabáková et al. Cell Death & Disease
- MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells
- (2018) Katerina Cerna et al. LEUKEMIA
- Extracellular vesicles and their nucleic acids for biomarker discovery
- (2018) Fatemeh Momen-Heravi et al. PHARMACOLOGY & THERAPEUTICS
- An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets MET and AXL in triple-negative breast cancer
- (2018) Shadan Hajalirezay Yazdi et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma
- (2018) Chanatip Metheetrairut et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1
- (2018) Meryem Gülfem Öner et al. GASTROENTEROLOGY
- LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling
- (2018) Hua Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Tumor expression of miR-34a-3p is an independent predictor of recurrence in non–muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram
- (2018) Jaroslav Juracek et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Pan-cancer characterisation of microRNA across cancer hallmarks reveals microRNA-mediated downregulation of tumour suppressors
- (2018) Andrew Dhawan et al. Nature Communications
- Butyl benzyl phthalate promotes prostate cancer cell proliferation through miR-34a downregulation
- (2018) Mingming Zhu et al. TOXICOLOGY IN VITRO
- c-Myc, RMRP, and miR-34a-5p form a positive-feedback loop to regulate cell proliferation and apoptosis in multiple myeloma
- (2018) Xichun Xiao et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence
- (2017) Federica Ganci et al. MODERN PATHOLOGY
- Regulation of miR-34 Family in Neuronal Development
- (2017) Abhishek Jauhari et al. MOLECULAR NEUROBIOLOGY
- Alternative mechanisms of miR-34a regulation in cancer
- (2017) Eva Slabáková et al. Cell Death & Disease
- A sequential EMT-MET mechanism drives the differentiation of human embryonic stem cells towards hepatocytes
- (2017) Qiuhong Li et al. Nature Communications
- Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity
- (2017) Jie-Ning Zhu et al. Scientific Reports
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment
- (2016) Stefan Hartmann et al. CLINICAL CANCER RESEARCH
- In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
- (2015) Yunching Chen et al. ADVANCED DRUG DELIVERY REVIEWS
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET
- (2015) BIN WEI et al. Molecular Medicine Reports
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS
- (2015) Fatemeh Momen-Heravi et al. Scientific Reports
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- Immunosuppressive Myeloid Cells Induced by Chemotherapy Attenuate Antitumor CD4+ T-Cell Responses through the PD-1-PD-L1 Axis
- (2014) Z.-C. Ding et al. CANCER RESEARCH
- A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
- (2014) N. Okada et al. GENES & DEVELOPMENT
- MicroRNA-34a: a potential therapeutic target in human cancer
- (2014) X J Li et al. Cell Death & Disease
- Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and -Catenin Predicts Distant Metastasis of Colon Cancer
- (2012) H. Siemens et al. CLINICAL CANCER RESEARCH
- Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
- (2011) Rebekka Krumbach et al. EUROPEAN JOURNAL OF CANCER
- The Fate of miRNA* Strand through Evolutionary Analysis: Implication for Degradation As Merely Carrier Strand or Potential Regulatory Molecule?
- (2010) Li Guo et al. PLoS One
- The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
- (2009) T. Y. Seiwert et al. CANCER RESEARCH
- miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells
- (2008) Na Li et al. CANCER LETTERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started